Real World Evidence
Dendrite Clinical Systems is a global leader in the area of clinical registries with an extensive experience in the field of Real World Evidence studies.
Real World Evidence goes beyond traditional controlled clinical trials. Pharmaceutical and medical device companies can use Real World Evidence data to inform stakeholders about a product's use, treatment patterns (standards of care), benefits and cost effectiveness to gain and defend market access, inform the design of products and trials and transform their relationships with clinicians from a supplier to a collaborator.
Large scale Real World Evidence data has not been available until recently – this is a major opportunity to demonstrate the value of your products. All of the major pharmaceutical companies have recently initiated Real World Evidence projects to inform product development and/or commercial decisions. Post market research has been the only growing area in the clinical research field in recent years. Indeed, if pharmaceutical and medical device companies do not take the initiative and lead the development of compelling real world cost-effectiveness arguments, regulatory agencies will create their own potentially unfavourable product narratives of which we have seen multiple examples already.
While there may be various sources of real world clinical information (such as Electronic Patient Record systems), implementation experience has proven that this information is mostly sporadic, incomplete and difficult to reconcile and analyse, particularly on a large scale. Clinical registries have proven to be the main source of scientifically robust large scale Real World Evidence to date.
Our customer dedication and delivery track record is impeccable. We would be delighted to work with you to help you design and support your Real World Evidence project.
Please contact us to discuss your Real World Evidence project:
Email: rwe@e-dendrite.com
Phone: +44 20 8949 8999 (Dr Alexey Brovko)
The Fifth IFSO Global Registry Report (2019) has been released at the XXIV World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) in Madrid, Spain. Published by Dendrite Clinical Systems, under the auspices of the IFSO, the publication reports data from more than 60 countries on over 833,000 operations including baseline obesity-related disease, operation types, operative outcomes and disease status after bariatric surgery.
Dendrite Clinical Systems has announced the installation of its National Bariatric Surgical Registry software at the Sheik Al Jaber Al Sabah Hospital, in Kuwait. The Sheik Al Jaber Al Sabah Hospital, opened by His Highness the Amir Sheikh Sabah Al-Ahmad Al- Jaber Al-Sabah in November 2018, consists of five towering 10-stories structures built on a 220,000 square meters and has a hospital bed capacity of around 1,160 with 36 operation rooms, a medical centre, a helipad and a parking lot accommodating some 5,000 vehicles.
Dendrite Clinical Systems and the Queen Mary Hospital in Hong Kong have launched the Asian Hypospadias Outcome Registry (AHOR), is a prospective web-based patient registry that will collect, record and analyse the treatment and outcomes of patients undergoing surgical repair.
Dendrite Clinical Systems has launched its ‘One-button push’ outcomes module, allowing clinicians to instantly produce their outcomes with the push of a single button. This enhancement is the latest in a series of advances incorporated into the company’s clinical registry software.
Dendrite Clinical Systems, the publisher of Bariatric News, is pleased to announce issue 40 of the newspaper is now available to view/download. The newspaper reports on research, technology, events and policy in the bariatric specialty, the latest clinical studies, policy changes and product news, the latest meetings and events, interviews prominent bariatric experts, and host debates between specialists on controversial topics.
Dendrite Clinical Systems – in collaboration with Haemotology Cancer Care (UCLH Charity), the Royal Free Charity, HaemSTAR (an organisation researching non-malignant haematology) and MPN Voice – have launched the MASCOT (Myeloproliferative Neoplasm Splanchnic Vein Thrombosis, MPN-SVT) Registry, a UK wide registry for patients with myeloproliferative diseases suffering from splanchnic or abdominal vein thrombosis.


